Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Pharma & Biotech
Pharma & Biotech
ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?
ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.
Pharma & Biotech
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.
Pharma & Biotech
Zentalis Pharmaceuticals aligns DENALI and ASPENOVA trials with evolving ovarian cancer treatment landscape
Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.
Pharma & Biotech
What BioXcel Therapeutics’ latest BXCL501 milestone could mean for neuropsychiatric care
Find out how BioXcel Therapeutics’ BXCL501 study could reshape acute stress care and influence future neuropsychiatric treatment pathways.
Pharma & Biotech
Can Arrowhead Pharmaceuticals expand plozasiran without the Ionis patent fight becoming a commercial overhang?
Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.
Pharma & Biotech
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
Pharma & Biotech
Why Galderma is turning ALASTIN into a clinic workflow strategy, not just a skincare brand
Galderma’s ALASTIN Signature Practices aim to embed skincare into aesthetic workflows. Read what this means for clinics, competition, and growth.
Pharma & Biotech
Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue
Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.